cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. It owns and operates consumer hemp-based CBD brands, such as cbdMD and Paw CBD. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. The company also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. It distributes its products through its e-commerce Website, third party e-commerce sites, wholesalers, and various brick and mortar retailers in the United States. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was founded in 2015 and is headquartered in Charlotte, North Carolina.
IPO Year: 2017
Exchange: AMEX
Website: cbdmd.com
Charlotte, North Carolina--(Newsfile Corp. - February 13, 2025) - (NYSE:YCBD) (NYSE:YCBDPA), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its new functional mushroom brand ATRx Labs today announced our financial results for the first quarter of fiscal year ended December 31, 2024. The Company started fiscal 2025 with a historic quarter, achieving sequential revenue growth, positive net income and, although a loss from operations, the first ever quarter of positive non-GAAP Adjusted EBITDA. The Company generated Net Income of $15,000, an approximate $1 million improvement from the prior
Charlotte, North Carolina--(Newsfile Corp. - February 7, 2025) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Thursday, February 13, 2025, to discuss the company's December 31, 2024 first quarter of fiscal year 2025 financial results and business progress.CONFERENCE CALL DETAILSThursday, February 13, 2025, 4:20 p.m. Eastern TimeUSA/Canada:844-763-8274International:647-484-8814Teleconference Replay dial in:USA/Canada:855-669-9658International:412-317-0088Replay Passcode:7970691Webcast/Webcast Replay link - available through March 13, 202
Charlotte, North Carolina--(Newsfile Corp. - January 15, 2025) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA), a leading and highly trusted CBD company known for its flagship brands cbdMD and Paw CBD, as well as its innovative functional mushroom brand ATRx Labs, today announced that the Company has fully satisfied the accrued interest and principal associated with its Senior Secured Convertible Notes. As of January 14, 2025, there are 6,262,833 shares of the Company's common stock issued and outstanding. "The Notes have been instrumental in providing us with the working capital cushion needed over the past year. By the full conversion of the Notes into shares of our common stock ahead of their ma
Charlotte, North Carolina--(Newsfile Corp. - January 8, 2025) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA), a leading and highly trusted CBD company known for its flagship brands cbdMD and Paw CBD, as well as its innovative functional mushroom brand ATRx Labs, today announced that the Company has reduced the principal amount outstanding on its Senior Secured Convertible Notes to approximately $56,000 as of January 8, 2025 as certain holders of the notes have converted amounts under the notes. Since the start of the year, the Company has issued an aggregate of 609,717 shares of common stock as a result of conversion requests and the aggregate balances under the notes have been reduced by approxima
Charlotte, North Carolina--(Newsfile Corp. - January 3, 2025) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBD) ,one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its new functional mushroom brand ATRx Labs, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated December 31, 2024, notifying the Company that it is no longer in compliance with an additional NYSE American continued listing standard. Specifically, the letter states that the Company is not in compliance with the continued listing standard set forth in Section 1003(a)(i) of the NYSE Amer
Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA), a leading and highly trusted CBD company known for its flagship brands cbdMD and Paw CBD, as well as its innovative functional mushroom brand ATRx Labs, today announced that T. Ronan Kennedy, the Company's Chief Executive Officer and Chief Financial Officer, has been appointed to its Board of Directors. The appointment became effective on December 18, 2024, expanding the board to five members."Over the past two years, Ronan has demonstrated exceptional leadership in stabilizing the business and reshaping cbdMD into a leaner, more efficient organization," said Scott Stephen, Chairman of cb
Finishes the year with a stronger cash position.Charlotte, North Carolina--(Newsfile Corp. - December 18, 2024) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its new functional mushroom brand ATRx Labs today announced our financial results for the full fiscal year ended September 30, 2024. For Fiscal 2024, we continued to make strong progress on our turnaround. The Company incurred a loss from operations of only $3.3 million, or a $19.1 million year-over-year improvement from the $22.9 million loss in the prior year. This is the second consecutive
Charlotte, North Carolina--(Newsfile Corp. - December 18, 2024) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Wednesday, December 18, 2024, to discuss the company's September 30, 2024 fourth quarter and fiscal year 2024 financial results and business progress.CONFERENCE CALL DETAILSWednesday, December 18, 2024, 4:20 p.m. Eastern TimeUSA/Canada:844-763-8274International:647-484-8814Teleconference Replay dial in:USA/Canada:855-669-9658International:412-317-0088Replay Passcode:5369354Webcast/Webcast Replay link - available through January
Charlotte, North Carolina--(Newsfile Corp. - December 17, 2024) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA), today announced that it has postponed the release of its financial results and conference call related to the fourth quarter and fiscal year ended September 30, 2024, which had previously been scheduled for December 17, 2024. cbdMD currently expects to issue its fourth quarter and fiscal year 2024 financial results after market close on Wednesday, December 18, 2024. The Company is delaying the release of financial results and the conference call because it needs additional time to complete its year-end reporting process. The Company currently expects to hold its conference call, on Wedne
Charlotte, North Carolina--(Newsfile Corp. - December 12, 2024) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA) one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Tuesday, December 17, 2024, to discuss the company's September 30, 2024 fourth quarter and fiscal year 2024 financial results and business progress.CONFERENCE CALL DETAILSTuesday, December 17, 2024, 4:20 p.m. Eastern TimeUSA/Canada:844-763-8274International:647-484-8814Teleconference Replay dial in:USA/Canada:855-669-9658International:412-317-0088Replay Passcode:4840580Webcast/Webcast Replay link - available through January 17,
PRE 14A - cbdMD, Inc. (0001644903) (Filer)
10-Q - cbdMD, Inc. (0001644903) (Filer)
10-K/A - cbdMD, Inc. (0001644903) (Filer)
8-K - cbdMD, Inc. (0001644903) (Filer)
8-K - cbdMD, Inc. (0001644903) (Filer)
8-K - cbdMD, Inc. (0001644903) (Filer)
10-K - cbdMD, Inc. (0001644903) (Filer)
8-K - cbdMD, Inc. (0001644903) (Filer)
8-K/A - cbdMD, Inc. (0001644903) (Filer)
8-K - cbdMD, Inc. (0001644903) (Filer)
Cantor Fitzgerald resumed coverage of cbdMD with a rating of Neutral and set a new price target of $3.25 from $4.10 previously
Cantor Fitzgerald reiterated coverage of cbdMD with a rating of Neutral and set a new price target of $4.30 from $3.60 previously
Charlotte, North Carolina--(Newsfile Corp. - June 22, 2023) - cbdMD (NYSE:YCBD), one of the nation's leading providers of premium cannabidiol (CBD) products, is delighted to announce the appointment of Dr. Lucille Vega as their new medical advisor. This collaboration marks an exciting chapter for both parties, as they play a pivotal role in educating the public about the numerous benefits of CBD and cbdMD's commitment to quality and transparency.As a brand that's renowned for its commitment to quality and innovation, cbdMD's comprehensive line of products spans across various categories and caters to a diverse range of consumer needs. By partnering with Dr. Vega, a highly qualified and passi
Charlotte, North Carolina--(Newsfile Corp. - January 11, 2023) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces the appointment of Shannon Charles as Chief Marketing Officer. Shannon is a veteran in health and wellness with over a decade of success in the Natural Product Industry. She has a proven record in driving growth across B&M retail, warehouse club stores, ecommerce, as well as international markets. Shannon's leadership has supported the successful brand stories of Naturade, NeoCell, and NutraNext, which the latter was ultimately acquired by The Clorox Co during her tenure. "We are thrilled to h
Martin Sumichrast resigns as CEO, Board MemberCharlotte, North Carolina--(Newsfile Corp. - June 13, 2022) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA), announced today that Martin Sumichrast has resigned as CEO and member of the Board of Directors, effective immediately. Board member Scott Stephen was named Board Chair and board member Scott Coffman, former co-CEO and the operating company founder, will consult with the Board of Directors in leading the company until a new CEO is named."We appreciate the years of service that Marty has given to our Company since its founding. However, we believe it is in the best interest of cbdMD, our employees, and our investors for him to step down." said Step
SCOTTSDALE, AZ / ACCESSWIRE / June 3, 2021 / Today CBD Life Sciences (OTC:CBDL) through its wholly owned subsidiary, LBC Bioscience Inc. is proud to announce that they have appointed Matthew McGee to serve as Chief Marketing Officer of the Company."I am over the top excited to assume the role of Chief Marketing Officer of CBD Life Sciences Inc," Mr. McGee said. "I look forward to growing the current success that CBD Life Sciences has achieved. I couldn't be anymore thankful for this wonderful opportunity, and I look forward to grow the company further, expand sales and bring in more revenue along with more customers as I have already started developing an amazingly effective strategic plan t
Charlotte, North Carolina--(Newsfile Corp. - February 13, 2025) - (NYSE:YCBD) (NYSE:YCBDPA), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its new functional mushroom brand ATRx Labs today announced our financial results for the first quarter of fiscal year ended December 31, 2024. The Company started fiscal 2025 with a historic quarter, achieving sequential revenue growth, positive net income and, although a loss from operations, the first ever quarter of positive non-GAAP Adjusted EBITDA. The Company generated Net Income of $15,000, an approximate $1 million improvement from the prior
Charlotte, North Carolina--(Newsfile Corp. - February 7, 2025) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Thursday, February 13, 2025, to discuss the company's December 31, 2024 first quarter of fiscal year 2025 financial results and business progress.CONFERENCE CALL DETAILSThursday, February 13, 2025, 4:20 p.m. Eastern TimeUSA/Canada:844-763-8274International:647-484-8814Teleconference Replay dial in:USA/Canada:855-669-9658International:412-317-0088Replay Passcode:7970691Webcast/Webcast Replay link - available through March 13, 202
Charlotte, North Carolina--(Newsfile Corp. - January 3, 2025) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBD) ,one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its new functional mushroom brand ATRx Labs, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated December 31, 2024, notifying the Company that it is no longer in compliance with an additional NYSE American continued listing standard. Specifically, the letter states that the Company is not in compliance with the continued listing standard set forth in Section 1003(a)(i) of the NYSE Amer
Finishes the year with a stronger cash position.Charlotte, North Carolina--(Newsfile Corp. - December 18, 2024) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its new functional mushroom brand ATRx Labs today announced our financial results for the full fiscal year ended September 30, 2024. For Fiscal 2024, we continued to make strong progress on our turnaround. The Company incurred a loss from operations of only $3.3 million, or a $19.1 million year-over-year improvement from the $22.9 million loss in the prior year. This is the second consecutive
Charlotte, North Carolina--(Newsfile Corp. - December 18, 2024) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Wednesday, December 18, 2024, to discuss the company's September 30, 2024 fourth quarter and fiscal year 2024 financial results and business progress.CONFERENCE CALL DETAILSWednesday, December 18, 2024, 4:20 p.m. Eastern TimeUSA/Canada:844-763-8274International:647-484-8814Teleconference Replay dial in:USA/Canada:855-669-9658International:412-317-0088Replay Passcode:5369354Webcast/Webcast Replay link - available through January
Charlotte, North Carolina--(Newsfile Corp. - December 17, 2024) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA), today announced that it has postponed the release of its financial results and conference call related to the fourth quarter and fiscal year ended September 30, 2024, which had previously been scheduled for December 17, 2024. cbdMD currently expects to issue its fourth quarter and fiscal year 2024 financial results after market close on Wednesday, December 18, 2024. The Company is delaying the release of financial results and the conference call because it needs additional time to complete its year-end reporting process. The Company currently expects to hold its conference call, on Wedne
Charlotte, North Carolina--(Newsfile Corp. - December 12, 2024) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBDPA) one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Tuesday, December 17, 2024, to discuss the company's September 30, 2024 fourth quarter and fiscal year 2024 financial results and business progress.CONFERENCE CALL DETAILSTuesday, December 17, 2024, 4:20 p.m. Eastern TimeUSA/Canada:844-763-8274International:647-484-8814Teleconference Replay dial in:USA/Canada:855-669-9658International:412-317-0088Replay Passcode:4840580Webcast/Webcast Replay link - available through January 17,
Charlotte, North Carolina--(Newsfile Corp. - August 26, 2024) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBD), one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its functional mushroom brand ATRx Labs, today announced that it received notice from the NYSE American LLC that it had accepted the Company's plan to regain compliance with the NYSE American continued listing standards and granted a plan period through December 5, 2025. As previously disclosed on June 5, 2024, the Company received a letter from the NYSE American stating that the Company was not in compliance with the continued listing standard
cbdMD Achieves Significant Reduction in Operating Loss as Operational Efficiencies Significantly Improve in Q3 2024Charlotte, North Carolina--(Newsfile Corp. - August 14, 2024) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBD) one of the nation's leading and most highly trusted and recognized CBD companies, and operator of the leading CBD brands cbdMD and Paw CBD, along with its new functional mushroom brand ATRx Labs today announced our financial results for our third quarter of fiscal 2024 ending June 30, 2024. This quarter, cbdMD made significant strides in its strategic objectives. Year-over-year, operational losses improved markedly, shrinking from $1.8 million in the third quarter of fiscal 2023 t
Charlotte, North Carolina--(Newsfile Corp. - August 5, 2024) - cbdMD, Inc. (NYSE:YCBD) (NYSE:YCBD), one of the nation's leading, highly trusted and widely recognized CBD companies, today announces that it will host a conference call at 4:20 p.m., Eastern Time, on Wednesday, August 14, 2024, to discuss the company's June 30, 2024 third quarter of fiscal 2024 financial results and business progress.CONFERENCE CALL DETAILSWednesday August 14, 2024, 4:20 p.m. Eastern TimeUSA/Canada:844-763-8274International:647-484-8814Teleconference Replay dial in:USA/Canada:877-344-7529International:412-317-0088Replay Passcode:5067217Webcast/Webcast Replay link - available through August 14, 2025: https://www.
4 - cbdMD, Inc. (0001644903) (Issuer)
4 - cbdMD, Inc. (0001644903) (Issuer)
4 - cbdMD, Inc. (0001644903) (Issuer)
3 - cbdMD, Inc. (0001644903) (Issuer)
4 - cbdMD, Inc. (0001644903) (Issuer)
4 - cbdMD, Inc. (0001644903) (Issuer)
4 - cbdMD, Inc. (0001644903) (Issuer)
4 - cbdMD, Inc. (0001644903) (Issuer)
4 - cbdMD, Inc. (0001644903) (Issuer)
4 - cbdMD, Inc. (0001644903) (Issuer)
SC 13D/A - cbdMD, Inc. (0001644903) (Subject)
SC 13D/A - cbdMD, Inc. (0001644903) (Subject)
SC 13D/A - cbdMD, Inc. (0001644903) (Subject)
SC 13D/A - cbdMD, Inc. (0001644903) (Subject)
SC 13D/A - cbdMD, Inc. (0001644903) (Subject)
SC 13D/A - cbdMD, Inc. (0001644903) (Subject)
SC 13D/A - cbdMD, Inc. (0001644903) (Subject)
SC 13D/A - cbdMD, Inc. (0001644903) (Subject)